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Abstract
Objective: A systematic review and meta-analysis was conducted to investigate if
glycemic control measured by glycated hemoglobin (HbA1c) levels near diagnosis are
predictive of future glycemic outcomes and vascular complications in childhood onset
type 1 diabetes (T1D).
Methods: Evidence was gathered using electronic databases (MEDLINE, EMBASE,
Web of Science, CINAHL, Scopus, and Cochrane Library up to February 2017) and
snowballing techniques. Studies investigating the association between the exposure
“early glycemic control” and main outcome: “tracking of early control” and secondary
outcome: risk of future complications; in children and young people aged 0 to
19 years at baseline; were systematically double-reviewed, quality assessed, and out-
come data extracted for synthesis and meta-analysis.
Findings: Five studies (N= 4227 participants) were eligible. HbA1c levels were sub-
optimal throughout the study period but tended to stabilize in a “track” by 6months
after T1D diagnosis. The group with low HbA1c <53mmol/mol (<7%) at baseline had
lower long-term HbA1c levels than the higher HbA1c group. The estimated standard-
ized mean difference between the sub groups showed a reduction of HbA1c levels
on average by 1.6% (range−0.95% to −2.28%) from baseline. Only one study investi-
gated the association between early glycemic control and development of vascular
complications in childhood onset T1D.
Interpretations: Glycemic control after the first few months of childhood onset T1D,
remains stable but sub-optimal for a decade. The low and high HbA1c levels at
ABBREVIATIONS: DCCT, The Diabetes Control and Complications Trial; EPPI, Evidence for
Policy and Practice Information; FE, Fixed effects model; HbA1c, Hemoglobin A1c; RE,
Random effects model; PROSPERO, International Prospective Register for systematic
Reviews; T1D, Type 1 diabetes.
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baseline seem to “track” in their respective tracks during the 10-year follow-up, how-
ever, the initial difference between groups narrows over time.
PROSPERO: CRD42015024546 http://www.crd.york.ac.uk/PROSPERO/display_
record.asp?ID=CRD42015024546
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1 | INTRODUCTION
Glycated hemoglobin (HbA1c) levels, a measure for glycemic control is
the main predictor of long-term type 1 diabetes (T1D) outcomes.1–3
HbA1c levels are highest at diagnosis, but improve after insulin treat-
ment and remain stable in most T1D patients. However, a few find it
challenging to maintain good glycemic control despite targeted or
intensive interventions, as they go through various stages in life.4,5
Studies mainly in adults have shown a link between poor glycemic
control in the early phase following T1D diagnosis and long-term
HbA1c levels, with an increased risk of developing vascular complica-
tions and mortality.6,7 The risk of vascular complications is likely to be
greater for childhood onset T1D, because of a longer duration of gly-
cemic exposure8 and pathophysiological factors, such as reduced insu-
lin sensitivity and psychosocial behaviors, such as insulin
omission.9–11 For childhood onset T1D, some observational studies
indicate an association between poor glycemic control within 1 or
2 years of diagnosis and vascular complications in later life.12–14
Others suggest that mean HbA1c levels nearer to diagnosis are pre-
dictive of HbA1c levels in the subsequent years, even lifetime, regard-
less of the type of insulin regimen.15–17 This phenomenon, also
known as glycemic “tracking,” is poorly understood.18 It is unclear
exactly when and in whom the phenomenon of “tracking” of HbA1c
occurs in childhood onset T1D and if it is because of the natural his-
tory of T1D. It is therefore important to investigate the evidence on
this phenomenon to identify if there exists a window period in the ini-
tial phase of T1D diagnosis, during which appropriate resources could
be mobilized to deliver targeted interventions to those at risk of
developing poorer long-term glycemic outcomes and vascular
complications.
The purpose of our study was to carry out a systematic review
and meta-analysis of the evidence assessing the impact of early glyce-
mic control in children (followed for at least 5 years from diagnosis) on
tracking of early control and the risk of developing vascular
complications.
2 | METHODS
This review is part of a series of systematic reviews of evidence on
the effects of early glycemic control in childhood onset T1D. The
review protocol was registered in PROSPERO (Registration number:
CRD42015024546) and a detailed protocol published.19 We followed
the review methods for the rigorous conduct and reporting of system-
atic reviews for policy and practice as described by the Evidence for
Policy and Practice Information (EPPI) Centre20 which are as per PRI-
SMA guidelines.21
2.1 | Search strategy
A refined search strategy was designed after a number of initial itera-
tive scoping searches, with input from experts in the field to maximize
capturing of key publications. Three sets of search terms were used
relating to population (children and young people diagnosed with
T1D), exposure (terms to capture observational, intervention, qualita-
tive studies, and review articles relating to early diabetes control) and
outcome (complications, mortality, glycemic tracking i.e., metabolic
memory) (Additional File 1).
Six electronic databases: (MEDLINE and EMBASE through OVID,
Web of Science through Thompson Reuters, CINAHL Plus through
EBSCO, Scopus through Elsevier, and the Cochrane Library), were
double searched in parallel by HC & VMP from inception to December
2014 and updated in February 2017 by using a combination of free
text and Thesaurus or MeSH terms (Additional File 2). No time-period
or language restrictions were applied. All identified articles from elec-
tronic databases were imported into Endnote and de-duplicated for
further review. This was supplemented by hand-searching of refer-
ence lists of studies and reviews, gray literature, personal databases
and contacting experts and authors of included studies for additional
or unpublished data.
2.2 | Study selection
Interventional and observational studies with a follow-up of ≥5 years
from diagnosis of T1D which described and quantified the association
between early glycemic control (defined as glycemic control within
2 years of diagnosis of T1D) AND long-term glycemic tracking
(defined as settling of HbA1c levels into long-term tracks of either >
or <7% ie, 53mmol/mol) and risk of future complications in children
and young people aged 0 to 19 years at baseline were included
(Additional File 3).
In addition to running electronic database searches in parallel
(HC and VMP), sub-samples of papers were double-reviewed (DC and
VMP), at each stage of the review process (title and abstract screen-
ing, data extraction and quality assessment). The interrater reliability
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for study selection was substantial.22 Full texts of abstracts appearing
to meet the inclusion criteria were retrieved and their status was
recorded in a pre-piloted excel spread-sheet, which included specific
study details and reasons for exclusion (for excluded studies). No for-
eign language papers were identified. Articles were re-examined
(DC and VMP) if there was uncertainty about inclusion criteria and
disagreements were resolved at team meetings.
2.3 | Data extraction
Data from included studies were extracted, analyzed, and synthesized
by one reviewer (VMP). A proportion of shortlisted studies were also
independently double reviewed and data extracted (DC and RA). From
observational studies, data on HbA1c levels were extracted at all
available time points from diagnosis. Data on HbA1c tracking and the
association between early glycemic control and chronic complications
or markers of chronic complications at follow-up were extracted
(Additional File 4). Authors of included studies were contacted for
clarity and additional information on HbA1c tracking data where nec-
essary. The main outcome of interest was tracking of early glycemic
control based on HbA1c measurements as percentage (DCCT) and/or
mmol/mol (International Federation of Clinical Chemistry) units. The
secondary outcome of interest was the impact of early glycemic con-
trol on the development of micro and macro vascular complications
during the long-term follow-up period.
2.4 | Quality assessment
The quality of included studies was assessed independently by two
reviewers (DC and VMP) using the quality assessment criteria by the
EPPI Centre.20 Any disagreements were resolved by consensus.
Scores were based on six items focusing on both internal and external
validity (Additional File 5). Observational studies were classified as
high (≥5), intermediate3,4 or low (≤2) quality based on the number of
quality criteria met out of a maximum assessment score of six.
2.5 | Statistical analysis
Information extracted from included studies were summarized
through descriptive narrative synthesis and meta-analysis.23 All statis-
tical analyses were conducted by one reviewer (VMP) and were veri-
fied by a second reviewer (JB). The sample size, mean HbA1c
measurements and SD or SE were available at population level and/or
for categorized low and high HbA1c groups. Where not reported, the
SE of the study at each time point was calculated using the reported
SD and the group sample sizes. Baseline period included 3 to
6months from T1D diagnosis. Mean HbA1c levels at diagnosis was
not included in the main meta-analysis as by definition they were
measured prior to exposure of glycemic control with insulin therapy.
The effect sizes and their SE were divided with SD to obtain standard-
ized mean differences (SMD).24
The primary outcome was the population mean HbA1c level at
baseline (0, 3, and 6months of diagnosis), 1, 2, 3, 5, 7, and 10years
follow-up. A further primary outcome was the difference in HbA1c
levels between the low HbA1c (<7% at baseline) group (considered
the “treated/exposed” group) and the high HbA1c group (≥7% at
baseline) (the “control” group), reported as standardized mean differ-
ences. If multiple measurements of HbA1c were reported at follow-up
then these measures were combined within each study before meta-
analysis. Heterogeneity between studies was expected and therefore
both fixed effects (FE, inverse variance) and random effects (RE, Der-
simonian, and Laird) models were used to pool the effect sizes and
reported using forest plots.25 The heterogeneity between studies was
assessed using the χ2 test for heterogeneity and I2 statistics.26 The
meta-analyses were carried using the metan command in STATA
15, StataCorp, College Station, Texas.
For glycated hemoglobin, the estimated pooled standardized mean
differences were converted into absolute units, to facilitate clinical
interpretation, by multiplying the estimate by the pooled SD of all
included studies of the meta-analysis.
Furthermore, the long-term population average HbA1c trajectory
from each study was plotted alongside the overall estimate at all-time
points of follow-up obtained from the meta-analysis. The trajectories
of HbA1c sub groups (low v/s high) in each study were also plotted.
The robustness of the meta-analysis to the choice of meta-
analysis model was assessed by comparing FE and RE pooled stan-
dardized effect sizes. In a sensitivity analysis we excluded studies in
pre-school children.
Assessing publication bias using the funnel plots, the Begg's rank
correlation test or the Egger's linear regression test was deemed inap-
propriate as there were insufficient studies included in the review.
Because of the small number of included studies, meta-regression
was not appropriate to explore heterogeneity between studies or to
investigate if there were other potential factors that could be inde-
pendently associated with long-term glycemic control. A minimum of
10 studies per study level parameter would be needed for
meta-regression.
Only one included study assessed the association of micro and
macro-vascular complications with early glycemic control, which pre-
cluded a meta-analysis and results of which were narrated separately.
3 | RESULTS
The literature search strategy on glycemic control in childhood onset
T1D identified articles from individual databases (Medline through
OVID, n = 14688; Embase through OVID, n = 843; Web of Science
through Thompson Reuters, n = 2734; CINAHL Plus through EBSCO,
n = 1185; Scopusthrough Elsevier, n = 2837 and Cochrane library,
n = 4052). After de-duplication 21063 articles were screened, out of
which 390 were shortlisted for full review (Figure 1). There was good
agreement between reviewers on identifying abstracts for full text
review. A total of 385 studies were excluded from the systematic
review and meta-analysis for reasons shown in Figure 1. Five fairly
recent studies24,27–30 conducted in developed countries (Israel, Scot-
land, Sweden, and USA) with a total of 4227 participants met the
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inclusion criteria of the systematic review. The studies investigated
national,24 regional,27 Children's hospital,29 academic medical centre30
and clinic28 level data.
3.1 | Characteristics of included studies
The Swedish cohort study24 consisted of 1543 children and adoles-
cents (920 males) from two nationwide population-based Swedish
registries (Swedish Pediatric Quality Registry and Swedish National
Diabetes Register) covering a period from year 2000 to 2010. The
mean age at diagnosis was 13.9 (range 5.0-19.0) years and the mean
follow-up was for 7.1 ± 2.5 (range 1.0-12.0) years. The study investi-
gated whether high mean HbA1c values 3 to 15 months after
diagnosis of T1D in childhood was associated with future glycemic
control, albuminuria and retinopathy in early adulthood.
The American study29 prospectively investigated, between the
years 1993 and 2009, whether age at diagnosis, gender, ethnicity,
diagnostic era (year of diagnosis) and type of insulin therapy were
associated with tracking of glycemic control at 5 years follow-up post
diagnosis of T1D. A total of 2218 (1166 males) mainly non-Hispanic
Caucasian (86.1%) children and adolescents participants with a mean
age of 9.0 ± 4.1 years at diagnosis (range 0-20 years), were identified
from the Children's Mercy Hospital T1Ds in pediatrics database,
USA. Insulin therapy (split regimen dosing, multiple daily injections
and continuous subcutaneous insulin infusion) and diagnostic
methods used to analyze HbA1c varied during the study period.
Information on the socio-economic status and T1D history in family
was not reported.
The other American study30 followed 138 children (71 males and
91.5% white) at an academic medical center of Pediatric
Endocrinology/Diabetology at Riley Hospital for Children, Indiana,
USA and investigated whether long-term HbA1c differed as a result
of receiving diabetes related education during the years 1998 to
2002. The mean age at diagnosis was 6.8 ± 3.3 years (age range:
1.1-13.9 years). Details of insulin therapy was not reported.
The Scottish study27 retrospectively investigated HbA1c tracking
among 155 children (74 males), aged ≤16 years (range 0 to 16 years),
from the regional database of the National Health Service (NHS) High-
land Pediatric diabetic services followed for a median of 4.10 (range
0 to 15.0) years from diagnosis between the years 1993 and 2012.
The cohort had limited ethnic diversity, low use of intensive insulin
therapy and no use of pump therapy.
The Israeli study28 was a retrospective observational study, inves-
tigating HbA1c tracking in 173 mainly Jewish (84.4%) preschool aged
children (84 males) aged 0.5 to 6.5 years at diagnosis between 1993
and 2009 at a tertiary level diabetes clinic in Israel, with a median T1D
duration of 4.3 years (range 1 to 11 years) and followed up for 7 years
from T1D onset. All patients were advised on carbohydrate counting,
required to perform >6 self- blood glucose measurements per day and
both multiple daily injections and insulin pumps were used.
Further details of the data extracted from the five studies included
in the systematic review are in Table 1.
3.2 | Study quality
The quality of the observational studies was intermediate to high.
Two studies were assessed to be “high” quality with a score of
five each24,29 and the other three were of “intermediate” quality,
with scores of four27,30 and three28 out of a possible score of six
respectively. No studies included in the review were of low
quality.
Total yield of records from electronic database search
(after de-duplication): n = 21,063
Records excluded during title & abstract  
screen stage: n = 20,673
Full text articles retrieved for detailed review:
n = 390 
Studies included in this review: n = 5
(longitudinal observational studies)
Total articles excluded at this stage: n = 385
-Inappropriate study design n= 70
-Inappropriate study population n= 186
-Inappropriate outcomes/ measures n= 34
-No association data: n= 89
-Other (reports, thesis, and letters): n= 6
F IGURE 1 Stages of systematic
review of evidence on long-term
glycaemic control
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3.3 | Early HbA1c levels and long-term tracking
of glycemic control
All five studies included in the review assessed the association
between early glycemic control and later HbA1c levels. Population
mean HbA1c was available at various follow-up time points (0, 3,
6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, and 156 months after
T1D diagnosis). In addition, four studies provided data on the associa-
tion between early glycemic control and later HbA1c levels within sub
groups of low and high HbA1c identified at baseline.24,27–29
To study the impact of early glycemic control on later HbA1c
levels, data from all five studies could be pooled in the review. The
number of studies reporting the effect during each time point of the
study period varied. All studies reported sub-optimal estimated mean
long-term glycemic control at all of the investigated time points during
the 10-year follow-up period. The sample size varied from 25 to 2218
and the study periods ranged between years 1993 and 2012. After
using the population mean HbA1c and SE in the FE & RE models, the
estimated pooled magnitude of the mean HbA1c levels (95% CI) was
suboptimal at 11.56% (CI: 11.46, 11.66%) at diagnosis, 7.74% (CI:
7.68, 7.80%) after 3months 7.61% (CI: 7.47, 7.76%) after 6months,
7.79% (CI: 7.71, 7.87%) after 1 year, 7.90%(CI: 7.83, 7.98%) after
2 years, 7.94% (CI: 7.86, 8.03%) after 3 years, 8.57% (CI: 8.49, 8.65%)
after 5 years, 7.99% (CI: 7.85, 8.12%) after 7 years and 8.59% (CI:
8.24, 8.94%) after 10 years of T1D diagnosis.
The pooled results comparing the effect size results of the FE and
RE models were presented in forest plot (Figure 2) and the overall
effect estimates were also presented in a graph (Supplementary Fig-
ure 2). There was variation in glycemic control between countries in
children and adolescents during the 10-year study period. The test for
heterogeneity between studies was significantly high (I2 > 69%) at
almost all of the follow-up time points in the meta-analysis
(χ2 P < 0.05).
Further exploratory sub-group analysis indicates that heterogene-
ity was consistently high between studies, countries and populations.
For the assessment of early glycemic control (low and high HbA1c
identified at baseline) and what followed at various time points during
the study period, there were four studies with data that could be
pooled in the review. The HbA1c levels of the low HbA1c group
showed better improvement than the high HbA1c group during the
study period. The low and high HbA1c levels at baseline seem to
“track” in their respective tracks during the 10-year follow-up how-
ever, the initial difference between groups narrows over time
(Figure 3).
From the FE meta-analysis, the pooled standardized difference in
mean HbA1c levels between patients in the low HbA1c group and
those in the high HbA1c group with 95% CI was significant at −1.25
(−1.53, −0.97) after 6months, −0.85 (−0.95, −0.75) after 1 year,
−0.84 (−0.95, −0.74) after 2 years, −0.78 (−0.89, −0.66) after 3 years,
−0.44 (−0.54, −0.34) after 5 years, −0.75 (−0.94, −0.55) after 7 years
and− 0.32 (−0.63, −0.02) after 10 years of T1D diagnosis. The treat-
ment effect in absolute units was a reduction of HbA1c levels on
average by 1.6% (range− 0.95 to −2.28%) from baseline, which may
be clinically relevant (Table 2).
The study in pre-school aged children (mean age at diagnosis
3.8 ± 1.6 years) showed better control than the other studies with
older children.28 The heterogeneity levels were significantly high
(P = 0.001) at 1, 2, 3, and 5 years after diagnosis and were lower at
follow-up time points 0.5, 7, and 10 years after diagnosis (P > 0.7) in
the meta-analysis.
The meta-analysis was repeated after excluding the study in pre-
school aged children (Supplementary Figure 1). The pooled standardized
mean difference in HbA1c levels between patients in the low HbA1c
group and those in the high HbA1c group with 95% CI was slightly lower
at −1.10 (−1.56, −0.65) after 6months, −0.79 (−0.89, −0.69) after 1year,
−0.78 (−0.89, −0.67) after 2years, −0.71 (−0.83, −0.59) after 3years,
−0.41 (−0.51, −0.30) after 5 years, −0.72 (−0.92, −0.53) after 7years
and− 0.32 (−0.63, −0.02) after 10years of T1D diagnosis. The treatment
effect in absolute units was a reduction of HbA1c levels on an average
by 1.49% (range− 0.90 to −2.37%) from baseline. The test for heteroge-
neity showed improved results and was significantly high only at 5years
after diagnosis (P = 0.001) in the meta-analysis (Table 2).
Comparing the long-term HbA1c trajectories between studies rev-
ealed that the Israeli study in pre-school children yielded better long-
term control (Supplementary Figure 2). Individual study results sug-
gest that early glycemic control tracks during the follow-up in the ini-
tially low and high HbA1c groups (Supplementary Figure 3).
Because there were only five studies in the review, we could not
assess publication bias using the funnel plot, the Begg adjusted rank
correlation test or the Egger test as there was insufficient power to
distinguish real asymmetry from random chance.
3.4 | Association of early HbA1c levels and
complications risk
Only one longitudinal study24 investigated the association of early gly-
cemic control and future complications and met the inclusion criteria
for the systematic review. The study, adjusted for gender, T1D dura-
tion, age at diagnosis, physical activity, and smoking; and reported that
Swedish children with higher mean HbA1c levels of ≥8.7%
(≥70mmol/mol), 3 to 15 months after diagnosis were significantly more
likely to develop macroalbuminuria (OR: 14.3, 95% CI: 2.6-78.2,
P < 0.01), microalbuminuria (OR: 1.7, 95% CI: 0.8-3.4, P < 0.05) and reti-
nopathy (OR: 2.0, 95% CI: 1.2-3.1, P < 0.01) in early adulthood (mean
age: 21± 2.3 years, range: 18-29 years). The study also highlighted the
lack of physical activity, smoking, and female gender as predictors of
poor glycemic control. However, the role of insulin therapies and other
social and family factors on these observations was not reported.
4 | DISCUSSION
We identified five longitudinal studies investigating the impact of
early glycemic control on long-term glycemic control in children and
adolescents (<19 years) followed from diagnosis of T1D. In the meta-
10 MAZARELLO PAES ET AL.
 
FE: fixed effects; RE: random effects; N: number of participants; ES: pooled estimates of HbA1c in absolute units at various time
points; I-V: inverse variance; D+L:DerSimonian and Laird     
F IGURE 2 Summary of fixed effects and random effects models: Pooled estimates of overall glycaemic control at follow-up
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analysis of all included five studies, the overall mean HbA1c levels in
all studies were sub-optimal at all follow-up time points.
The meta-analysis of the four studies comparing initially low v/s
high HbA1c groups, indicates that the low HbA1c group showed over-
all slightly improved control than the high HbA1c group during the
study period. In addition, the meta-analyses suggests that the overall
glycemic control was stable in a “track” after 6months of childhood
onset T1D diagnosis. The low and high HbA1c levels at baseline also
seem to “track” in their respective tracks during the 10-year follow-
up. However, the initial difference between groups narrows over time.
The number of participants in the low HbA1c group was small and this
may have influenced the power to detect group differences.
Three of the included studies were of intermediate quality while
the remaining two were of high quality in reporting potential biases.
We adhered to strict systematic review procedures for study selec-
tion, data extraction and reporting to minimize reviewer related
SMD: standardised mean difference; CI: confidence interval; N: number of participants; SD: standard deviation; I-V: inverse variance;
D+L: DerSimonian and  Laird 
F IGURE 3 Summary of fixed effects and random effects models: Estimated standardized mean difference of glycated hemoglobin (HbA1c)
levels with 95% confidence interval between the low (exposed to glycaemic control) and high (unexposed to glycaemic control) HbA1c groups
during various time-points of follow-up
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biases. The age ranges and sample sizes varied between studies which
may have influenced the heterogeneity seen in the pooled estimates
of long-term glycemic control. Heterogeneity was reduced when the
study in pre-school children was excluded from the meta-analysis.
All studies included in the systematic review were conducted in
developed countries, which had dissimilar health system models and
this may have impacted the long-term glycemic outcomes. The study
period was between years 1993 and 2012, during which period
understanding of the disease and diagnostic methods for HbA1c test-
ing improved. This may have affected the interpretation of the HbA1c
measurements. Also, several changes were implemented during this
period in diabetes care, practice and management, through introduc-
tion of novel fast acting insulin formulations, intensive insulin treat-
ment and educational interventions. These and the improved
diagnostic and clinic factors may have played a role in improving the
overall glycemic trajectories in the participants as reported by other
studies.31,32
The sub-optimal HbA1c control estimated in the meta-analysis
during the follow-up period may be because of more participants with
higher HbA1c levels, age,33 endogenous and exogenous factors or
biological variation in the glycation phenotypes of children,34–36 psy-
chological factors particularly in older children.37,38 These are all fac-
tors which may also have increased the risk of developing or
progression of micro and macrovascular complications in those chil-
dren as a consequence of those higher HbA1c levels.39
The DCCT cohort were able to achieve HbA1c levels of 7%
(53mmol/mol)40 as compared with 8.3% (66mmol/mol) achieved
among more than 25000 patients from USA41 and 8.7%
(70.1 mmol/mol) achieved by the pediatric population of England and
Wales in the UK.42 This highlights the fact that, outside of a clinical
trial, achieving glycemic targets remains difficult. Hence robustly iden-
tifying factors early in the life course of childhood onset T1D that
influence future glycemic control and risk of complications remains an
important clinical research goal.
Only one study provided evidence that albuminuria and retinopa-
thy were associated with high mean HbA1c of ≥ 8.6% (≥70mmol/mol)
between 3 and 15 months after diagnosis of T1D.24 This is consistent
with findings by other studies, which did not meet our inclusion
criteria.6,17,43,44 It would be highly relevant for determining future
prognosis, if these outcomes could be confirmed in future studies.
Cardiovascular disease is the major cause of death in T1D
patients. Pre-symptomatic cardiovascular disease is evident in 100%
of young adults with T1D45 and there is evidence of accelerated ath-
erosclerotic processes46,47 and increased severity of cardiovascular
disease48 at an earlier age compared to the general population. Land-
mark trials show that intensive insulin therapy reduces cardiovascular
events in adults.6,49 Although differences in HbA1c account for most
of this benefit, multivariate analyses suggest that part of the reduced
risk is mediated by reduction in the incidence of diabetic renal dis-
ease.50 In children and young people with T1D, atherosclerosis is pre-
sent to a greater extent51 and the prevalence of cardiovascular risk
factors is greater52,53 than in the general population. Diabetic
nephropathy incidence accelerates during adolescence.54 These are allT
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strong indicators of a greatly elevated risk for future vascular diseases.
There is currently no evidence base for the effectiveness of ACE Inhi-
bition or statin treatments in adolescents with T1D although, the
important AdDIT Trial may inform practice in the coming years.55
Therefore currently, in order to reduce vascular complications risk, the
importance of achieving good glycemic control is arguably greater in
childhood compared to adult T1D populations.
The meta-analysis indicates that the overall glycemic control stabi-
lizes in a “track” after 6months of childhood onset T1D diagnosis and
pre-school aged children had better control throughout the follow-up
period. Furthermore, the low and high HbA1c levels at baseline also
seem to have metabolic memory, which shows HbA1c “tracking” dur-
ing the 10-year follow-up despite differences between the high and
low groups. This suggests there may be benefits of having good con-
trol during the initial few months of diagnosis. However, as these five
studies report temporal associations, an experimental study of an
intervention soon after diagnosis would be required to prove that bet-
ter early control results in better later control. This review may also
indicate a short window of opportunity to intervene and improve
long-term glycemic outcomes. It may therefore be beneficial to
develop clinical and educational strategies to identify and deliver
targeted interventions during this early phase to those at risk of hav-
ing poor glycemic control and to ensure that the HbA1c targets are
maintained in the long-term. There is currently no evidence on effec-
tiveness and timing of focused clinical interventions targeted at
changing these tracks.18 It would be useful to gather this evidence
and to explore further the mechanisms of this phenomenon in order
to deliver best care to newly diagnosed children and adolescents. The
findings of this review would be useful to policy makers, health pro-
fessionals and T1D patients to focus on designing interventions to
prevent sub-optimal glycemic outcomes and decrease the risk of
developing micro and macro vascular complications.
4.1 | Strengths and limitations of the review
The many strengths of this study include, being to our knowledge, the
first systematic review and meta-analysis to rigorously investigate
published and unpublished literature on the association of early glyce-
mic control in childhood onset T1D with glycemic tracking and future
risk of complications. Furthermore, this is the first review to rigorously
and systematically search and review all available evidence as per pre-
set inclusion/exclusion and quality assessment criteria. We have taken
utmost care to minimize study selection, reviewer related and publica-
tion bias. All of the included studies were intermediate to high quality.
But, there are limitations to this systematic review which need to
be considered. The diabetes diagnosis, care, and HbA1c outcome mea-
sures have evolved over the years and were not uniform across studies.
There was considerable heterogeneity between studies. The compara-
ble follow-up data was not available beyond 10years. We were unable
to investigate if other factors may have confounded the findings. The
small number of studies and the short duration of follow-up in studies
may have masked the true association with long-term glycemic control.
Although we made every effort to search for unpublished and gray
literature, we may have missed some that remain unreported because
of unethical practices in reporting or publication bias. The results of our
study may not be generalizable as they were mainly conducted in devel-
oped countries with varied health care system models.
4.2 | Review updating plans
The review will be updated if significant new evidence becomes avail-
able and results of the update review will be disseminated through
peer-reviewed publications, conference presentations and at meetings.
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